|
1
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Haggar FA and Boushey RP: Colorectal
cancer epidemiology: Incidence, mortality, survival, and risk
factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar :
|
|
3
|
Liu R, Huang S, Lei Y, Zhang T, Wang K,
Liu B, Nice EC, Xiang R, Xie K, Li J, et al: FGF8 promotes
colorectal cancer growth and metastasis by activating YAP1.
Oncotarget. 6:935–952. 2015.
|
|
4
|
Chairatvit K and Ngamkitidechakul C:
Control of cell proliferation via elevated NEDD8 conjugation in
oral squamous cell carcinoma. Mol Cell Biochem. 306:163–169. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Todd R, Hinds PW, Munger K, Rustgi AK,
Opitz OG, Suliman Y and Wong DT: Cell cycle dysregulation in oral
cancer. Crit Rev Oral Biol Med. 13:51–61. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Izzo JG, Papadimitrakopoulou VA, Li XQ,
Ibarguen H, Lee JS, Ro JY, El-Naggar A, Hong WK and Hittelman WN:
Dysregulated cyclin D1 expression early in head and neck
tumorigenesis: In vivo evidence for an association with subsequent
gene amplification. Oncogene. 17:2313–2322. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ayad NG, Rankin S, Murakami M,
Jebanathirajah J, Gygi S and Kirschner MW: Tome-1, a trigger of
mitotic entry, is degraded during G1 via the APC. Cell.
113:101–113. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smith A, Simanski S, Fallahi M and Ayad
NG: Redundant ubiquitin ligase activities regulate wee1 degradation
and mitotic entry. Cell Cycle. 6:2795–2799. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoshida K: Cell-cycle-dependent regulation
of the human and mouse Tome-1 promoters. FEBS Lett. 579:1488–1492.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kraft C: Mitotic entry: Tipping the
balance. Curr Biol. 13:R445–R446. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lim HH and Surana U: Tome-1, wee1, and the
onset of mitosis: Coupled destruction for timely entry. Mol Cell.
11:845–846. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jia L and Sun Y: RBX1/ROC1-SCF E3
ubiquitin ligase is required for mouse embryogenesis and cancer
cell survival. Cell Div. 4:162009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu Q, Fu J, Luo B, Huang M, Guo W, Lin Y,
Xie X and Xiao S: OY-TES-1 may regulate the malignant behavior of
liver cancer via NANOG, CD9, CCND2 and CDCA3: A bioinformatic
analysis combine with RNAi and oligonucleotide microarray. Oncol
Rep. 33:1965–1975. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Uchida F, Uzawa K, Kasamatsu A, Takatori
H, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H and Bukawa H:
Overexpression of cell cycle regulator CDCA3 promotes oral cancer
progression by enhancing cell proliferation with prevention of G1
phase arrest. BMC Cancer. 12:3212012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Adams MN, Burgess JT, He Y, Gately K,
Snell C, Zhang SD, Hooper JD, Richard DJ and O’Byrne KJ: Expression
of CDCA3 is a prognostic biomarker and potential therapeutic target
in non-small cell lung cancer. J Thorac Oncol. 12:1071–1084. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen J, Zhu S, Jiang N, Shang Z, Quan C
and Niu Y: HoxB3 promotes prostate cancer cell progression by
transactivating CDCA3. Cancer Lett. 330:217–224. 2013. View Article : Google Scholar
|
|
17
|
Benson AB III, Venook AP, Bekaii-Saab T,
Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ,
Fuchs CS, et al: National Comprehensive Cancer Network: Colon
cancer, version 3.2014. J Natl Compr Canc Netw. 12:1028–1059. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
19
|
Sun J, Shi R, Zhao S, Li X, Lu S, Bu H, Ma
X and Su C: E2F8, a direct target of miR-144, promotes papillary
thyroid cancer progression via regulating cell cycle. J Exp Clin
Cancer Res. 36:402017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Gong C, Mao H, Li Z, Fang Z, Chen
Q, Lin M, Jiang X, Hu Y, Wang W, et al: E2F1/SP3/STAT6 axis is
required for IL-4-induced epithelial-mesenchymal transition of
colorectal cancer cells. Int J Oncol. 53:567–578. 2018.PubMed/NCBI
|
|
21
|
Itzel T, Scholz P, Maass T, Krupp M,
Marquardt JU, Strand S, Becker D, Staib F, Binder H, Roessler S, et
al: Translating bioinformatics in oncology: Guilt-by-profiling
analysis and identification of KIF18B and CDCA3 as novel driver
genes in carcinogenesis. Bioinformatics. 31:216–224. 2015.
View Article : Google Scholar :
|
|
22
|
Egilmez R, Elagoz S and Kanik EA:
Cdk1/P34Cdc2 and P21waf expression in colorectal adenomas and
carcinomas. J Exp Clin Cancer Res. 20:549–552. 2001.
|
|
23
|
Pines J and Rieder CL: Re-staging mitosis:
A contemporary view of mitotic progression. Nat Cell Biol. 3:E3–E6.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Calvisi DF, Donninger H, Vos MD, Birrer
MJ, Gordon L, Leaner V and Clark GJ: NORE1A tumor suppressor
candidate modulates p21CIP1 via p53. Cancer Res. 69:4629–4637.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thaler S, Hähnel PS, Schad A, Dammann R
and Schuler M: RASSF1A mediates p21Cip1/Waf1-dependent cell cycle
arrest and senescence through modulation of the Raf-MEK-ERK pathway
and inhibition of Akt. Cancer Res. 69:1748–1757. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Niculescu AB III, Chen X, Smeets M, Hengst
L, Prives C and Reed SI: Effects of p21(Cip1/Waf1) at both the G1/S
and the G2/M cell cycle transitions: pRb is a critical determinant
in blocking DNA replication and in preventing endoreduplication.
Mol Cell Biol. 18:629–643. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stein JP, Ginsberg DA, Grossfeld GD,
Chatterjee SJ, Esrig D, Dickinson MG, Groshen S, Taylor CR, Jones
PA, Skinner DG, et al: Effect of p21WAF1/CIP1 expression on tumor
progression in bladder cancer. J Natl Cancer Inst. 90:1072–1079.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cai K and Dynlacht BD: Activity and nature
of p21(WAF1) complexes during the cell cycle. Proc Natl Acad Sci
USA. 95:12254–12259. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Parker SB, Eichele G, Zhang P, Rawls A,
Sands AT, Bradley A, Olson EN, Harper JW and Elledge SJ:
p53-independent expression of p21Cip1 in muscle and other
terminally differentiating cells. Science. 267:1024–1027. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peng YP, Zhu Y, Yin LD, Zhang JJ, Wei JS,
Liu X, Liu XC, Gao WT, Jiang KR and Miao Y: PEG10 overexpression
induced by E2F1promotes cell proliferation, migration, and invasion
in pancreatic cancer. J Exp Clin Cancer Res. 36:302017. View Article : Google Scholar
|
|
31
|
Teplyuk NM, Uhlmann EJ, Wong AH, Karmali
P, Basu M, Gabriely G, Jain A, Wang Y, Chiocca EA, Stephens R, et
al: MicroRNA-10b inhibition reduces E2F1-mediated transcription and
miR-15/16 activity in glioblastoma. Oncotarget. 6:3770–3783. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang E, Yin D, Han L, He X, Si X, Chen W,
Xia R, Xu T, Gu D, De W, et al: E2F1-induced upregulation of long
noncoding RNA LINC00668 predicts a poor prognosis of gastric cancer
and promotes cell proliferation through epigenetically silencing of
CKIs. Oncotarget. 7:23212–23226. 2016.PubMed/NCBI
|
|
33
|
Feldstein O, Ben-Hamo R, Bashari D, Efroni
S and Ginsberg D: RBM38 is a direct transcriptional target of E2F1
that limits E2F1-induced proliferation. Mol Cancer Res.
10:1169–1177. 2012. View Article : Google Scholar : PubMed/NCBI
|
